Compare SRRK & ASB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | ASB |
|---|---|---|
| Founded | 2012 | 1861 |
| Country | United States | United States |
| Employees | N/A | 4000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.2B |
| IPO Year | 2018 | N/A |
| Metric | SRRK | ASB |
|---|---|---|
| Price | $48.29 | $28.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $56.17 | $29.75 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.45% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.24 |
| Revenue Next Year | $534.24 | $8.86 |
| P/E Ratio | ★ N/A | $10.23 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $22.48 |
| 52 Week High | $51.63 | $29.52 |
| Indicator | SRRK | ASB |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 53.71 |
| Support Level | $45.28 | $27.23 |
| Resistance Level | $51.34 | $28.02 |
| Average True Range (ATR) | 2.39 | 0.54 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 50.94 | 48.22 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Associated Banc-Corp is a bank holding company based in the United States of America. The company, through its subsidiaries, provides a broad array of banking and non-banking products and services to individuals and businesses. The group operates in three reportable segments: Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty segment, which serves a wide range of customers, including larger businesses, developers, not-for-profits, municipalities, and financial institutions by providing lending and deposit solutions as well as support to deliver, fund, and manage such banking solutions.